Imagine facing metastatic lung cancer, where the disease has spread beyond the lungs. This is a tough battle, as traditional treatments often struggle to keep the cancer at bay. A new study is testing whether adding a specific type of radiation therapy, called liver stereotactic ablative radiotherapy, to standard drug treatments can provide better outcomes for patients. The goal is to see if this combination can help patients live longer without their cancer progressing. If successful, this approach could offer new hope for those with advanced lung cancer, potentially giving them more quality time with family and friends. However, it’s important to remember that this is still in the testing phase, and results can vary. More research will help clarify the benefits and risks, but for now, this study shines a light on promising new options for patients in need.
Could Targeted Radiation Therapy Offer Hope for Lung Cancer Patients?
Plain Language Summary
What this means for you:
New radiation therapy could give lung cancer patients more time with loved ones — a glimmer of hope in tough times. What this means for you:
New radiation therapy could give lung cancer patients more time with loved ones — a glimmer of hope in tough times. View Original Abstract ↓
Status: RECRUITING | Phase: PHASE2
Condition(s): Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-small Cell Carcinoma, NSCLC, NSCLC Stage IV
Intervention(s): L-SABR (RADIATION), Anti-PD-(L)1 based immunotherapy (BIOLOGICAL), Platinum based chemotherapy (DRUG)
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
Primary Outcome(s): Median progression-free survival
Enrollment: 68 (ESTIMATED)
Lead Sponsor: Memorial Sloan Kettering Cancer Center
Start: 2022-12-09 | Primary Completion: 2026-12-09